The development of exosome therapeutics from the bench depends on the manufacturing on a commercial scale. 

ILIAS Biologics Inc. is overcoming challenges with innovative platform technologies, including Pure-Exo®. 

Recently researchers of ILIAS published the review paper ‘Manufacturing Therapeutic Exosomes: from Bench to Industry' in Molecules and Cells.

This mini-review addresses exosome manufacturing challenges and emphasizes that it should go through the manufacturing, characterization, and formulation stages, production under Good Manufacturing Practice (GMP) conditions for clinical use to be commercialized.

Please find the publication at the link for the detail.

Link